F&C Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

F&C Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	$9.85M	Buy	64,733 +9,570	+17%	+$1.52M	0.12%	232
2013 Q4	$7.34M	Buy	55,163 +1,400	+3%	+$168K	0.09%	284
2013 Q3	$6.24M	Buy	53,763 +1,854	+4%	+$203K	0.08%	295
2013 Q2	$4.79M	Buy	+51,909	New	+$5M	0.07%	328

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

F&C Asset Management's ALXN Position: Q1 2014 in Review

F&C Asset Management increased its Alexion Pharmaceuticals (ALXN) stake by 17% in Q1 2014, buying an estimated $1.52M and bringing the position to 64,733 shares worth $9.85M. The position accounts for 0.12% of the portfolio, ranked #232.

F&C Asset Management first reported a position in ALXN in Q2 2013 and has held it in 4 quarters since. 504 funds tracked by Wall St. Rank hold ALXN as of Q1 2014.

F&C Asset Management held 64,733 shares of Alexion Pharmaceuticals worth $9.85M as of Q1 2014.
F&C Asset Management bought 9,570 Alexion Pharmaceuticals shares in Q1 2014, an estimated $1.52M.
Alexion Pharmaceuticals made up 0.12% of F&C Asset Management's portfolio in Q1 2014, its #232 holding.
F&C Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 4 quarters since.
504 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2014.

Based on F&C Asset Management's 13F filing for Q1 2014, filed 14 May 2014.